Publications
138
Citations
3,796
Est. group size
~13
Recurring co-author estimate
Active years
32
Publishing since 1995
Jonathan L. Slaughter's research focuses on the care of premature and newborn infants, particularly conditions like patent ductus arteriosus (a heart vessel abnormality common in preemies), neonatal jaundice (hyperbilirubinemia), and the effects of prenatal chemical or opioid exposure on infant development. His work often uses large hospital databases and population studies to evaluate treatment guidelines and real-world outcomes rather than laboratory experiments. This research aims to inform clinical guidelines and hospital practices for neonatal and pediatric care.
Publication output has grown substantially over the last decade, rising from about 4 papers per year in 2017-2018 to over 20 per year in 2023 and 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Gestational Exposure to 10 Classes of Priority Chemicals and Birth Outcomes in the ECHO Cohort
JAMA Network Open · 2026
- Expectant Management vs Medication for Patent Ductus Arteriosus in Preterm Infants
UNC Libraries · 2026
- Impact of the 2022 AAP Guidelines on Neonatal Hyperbilirubinemia Admissions: A PHIS Study
Hospital Pediatrics · 2025
- Kernicterus Case Incidence Unchanged Since the 2022 American Academy of Pediatrics Hyperbilirubinemia Guideline Revision
The Journal of Pediatrics · 2025
- A New Horizon for Understanding the Comparative Effectiveness for Cooling Prospectively Infants with Mild Encephalopathy
Clinics in Perinatology · 2024
- Neurodevelopmental outcomes in children prenatally exposed to opioid maintenance treatment: A population‐based study
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2024
- Advancing Understanding of Chemical Exposures and Maternal-child Health Through the U.S. Environmental Influences on Child Health Outcomes (ECHO) Program: A Scoping Review
Current Environmental Health Reports · 2024
- Real-World Evidence: What It Is and What It Can Tell Us According to the International Society for Pharmacoepidemiology (ISPE) Comparative Effectiveness Research (CER) Special Interest Group (SIG)
UNC Libraries · 2024
- Current Trends in Invasive Closure of Patent Ductus Arteriosus in Very Low Birth Weight Infants in United States Children's Hospitals, 2016-2021
The Journal of Pediatrics · 2023
- Optimizing therapeutic decision‐making for off‐label medicines use: A scoping review and consensus recommendations for improving practice and research<sup>+</sup>
Pharmacoepidemiology and Drug Safety · 2023
- Prenatal Exposure to Opioids and Neurodevelopmental Disorders in Children: A Bayesian Mediation Analysis
American Journal of Epidemiology · 2023
- Time to Stop Early Treatment of Patent Ductus Arteriosus?
New England Journal of Medicine · 2023
- Time to Stop Early Treatment of Patent Ductus Arteriosus?
Obstetric Anesthesia Digest · 2023
- Technical Report: Diagnosis and Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation
PEDIATRICS · 2022
- Pulmonary Hypertension in Preterm Infants Treated With Laser vs Anti–Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity
JAMA Ophthalmology · 2022
- Journal of Perinatology×14
- JAMA Network Open×12
- JAMA Pediatrics×9
- The Journal of Pediatrics×8
- Journal of the American Society of Nephrology×6
- Roopali Bapat
Medicine · The Ohio State University
- Gregory M. Sokol
Medicine · Indiana University
- Maria Jebbia
Medicine · The Ohio State University
- Leeann R. Pavlek
Medicine · The Ohio State University
- Jodi A. Ulloa
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile